NASDAQ · ARWR
Arrowhead Pharmaceuticals, Inc.
$59.88-$0.61 (-1.01%)
Arrowhead Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.29% below the high.
Loading market information…
OTC · SLNCF · USD
Stock price, earnings
Quote as of Oct 30, 2026, 07:14 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Silence Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Silence Therapeutics plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Silence Therapeutics plc, a biotechnology firm headquartered in London, United Kingdom, is dedicated to the discovery and advancement of pioneering ribonucleic acid (RNA) therapeutics. Its research and development efforts span key areas such as blood disorders, cardiovascular health, and other uncommon and metabolic ailments. Central to the company's approach is its proprietary mRNAi GalNAc Oligonucleotide Discovery platform, meticulously crafted to precisely target specific disease-causing genes, predominantly within the liver. This mechanism involves creating short interfering RNA (siRNA) molecules that activate the body's intrinsic RNA interference pathway, effectively breaking down messenger RNA (mRNA) sequences responsible for producing particular disease-associated proteins inside cells. Silence Therapeutics is actively developing a pipeline of therapeutic candidates. This includes SLN360, currently in Phase I clinical trials for the treatment of cardiovascular disease characterized by elevated lipoprotein levels. Furthermore, SLN124 is progressing through Phase I clinical trials for both non-transfusion dependent thalassemia and myelodysplastic syndrome, with ongoing development also focused on polycythemia vera. The company has forged strategic partnerships to broaden its reach and capabilities. It collaborates with AstraZeneca PLC to identify, develop, and commercialize small interfering RNA therapeutics addressing cardiovascular, renal, metabolic, and respiratory conditions. Another alliance is with Mallinckrodt Pharma IP Trading DAC, centered on developing and marketing RNAi drug targets designed to inhibit the complement cascade in various complement-mediated disorders. Additionally, Silence Therapeutics is working with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three confidential targets, utilizing its mRNAi GOLD platform. The organization, which operated as SR Pharma plc until its rebranding in May 2007, continues its mission under the name Silence Therapeutics plc.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:15 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $137.79K-97.39% vs estimate |
| Q4 2024 | Feb 27, 2025 | $0.02+132.78% vs estimate | $25.08M+270.54% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | -$0.09-94.38% vs estimate | $1.53M-73.92% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$59.88-$0.61 (-1.01%)
Arrowhead Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.29% below the high.
$43.52-$0.87 (-1.96%)
Ionis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.83% below the high.
$18.62-$0.61 (-3.17%)
Sarepta Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.55% below the high.
$16.88-$0.97 (-5.43%)
ADARx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.27% below the high.
$3.59-$0.04 (-1.1%)
Wave Life Sciences Ltd.’s quoted price sits in the lower half of its reported 52-week range, 83.48% below the high.
$11.00-$1.15 (-9.47%)
Arcturus Therapeutics Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.75% below the high.
$8.76-$0.07 (-0.79%)
Benitec Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.48% below the high.
$1.39-$0.05 (-3.47%)
ProQR Therapeutics N.V.’s quoted price sits in the lower half of its reported 52-week range, 50.53% below the high.
